

AWARD NUMBER: W81XWH-17-1-0471

TITLE: Detection and Characterization of Treatment Emergent Neuroendocrine Prostate Cancer Using Hyperpolarized ¹³C Magnetic Resonance

PRINCIPAL INVESTIGATOR: Renuka Sriram

CONTRACTING ORGANIZATION: University of California, San Francisco
San Francisco, CA 94143-2520

REPORT DATE: SEPTEMBER 2019

TYPE OF REPORT: Annual report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE SEPTEMBER 2019		2. REPORT TYPE ANNUAL REPORT		3. DATES COVERED 15AUG2018 - 14AUG2019	
4. TITLE AND SUBTITLE Detection and Characterization of Treatment Emergent Neuroendocrine Prostate Cancer Using Hyperpolarized ¹³ C Magnetic Resonance				5a. CONTRACT NUMBER PC160630	
				5b. GRANT NUMBER W81XWH-17-1-0471	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Renuka Sriram E-Mail: Renuka.sriram@ucsf.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California, San Francisco 1700 4th Street San Francisco, CA, 94158-2330				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The goal of this proposal is to discriminate biologically divergent treatment-emergent neuroendocrine prostate cancer (NEPC) from advanced adenocarcinoma based on the metabolic profile of NEPC tumors and to use real-time changes in metabolism to monitor therapeutic efficacy by using novel hyperpolarized (HP) ¹³ C metabolic imaging techniques. In the 1 st year of funding, our major activities focused on collating preliminary studies for Aims 1 and 2 to establish feasibility. To this end for Aim 1, the probes (glutamine and acetate) were optimized for hyperpolarization technique and tested in cells and baseline TRMAP studies. Correlative measures of NEPC presence were developed using ELISA and serum enzyme activities in addition to IHC quantification. Furthermore preliminary metabolic profiling of TRMAP tumors showed altered substrate utilization with the onset of CRPC further strengthening our hypothesis of metabolic adaptations with treatment resistance. For Aim2, we did exhaustive feasibility of labeling studies in biopsy samples, and for the first time showed viability and detected ex vivo measures of glycolytic activity.					
15. SUBJECT TERMS Hyperpolarized ¹³ C MRI, pyruvate, treatment emergent neuroendocrine prostate cancer, metabolism					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 21	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	1
2. Keywords.....	1
3. Accomplishments.....	1
4. Impact.....	5
5. Changes/Problems.....	5
6. Products.....	5
7. Participants & Other Collaborating Organizations.....	7
8. Special Reporting Requirements.....	n/a
9. Appendices.....	9

1. INTRODUCTION

The goal of this proposal is to discriminate biologically divergent treatment-emergent neuroendocrine prostate cancer (NEPC) from advanced adenocarcinoma based on the metabolic profile of NEPC tumors and to use real-time changes in metabolism to monitor therapeutic efficacy by using novel hyperpolarized (HP) ^{13}C metabolic imaging techniques in order to develop a clinically translatable non-invasive imaging tool for early detection and appropriate therapeutic intervention. There is no current imaging or other diagnostic tools available to non-invasively detect NEPC. The successful completion of this project will confirm the utility of HP lactate production as a metabolic biomarker of NEPC and investigate the utility of acetyl CoA and glutamate as novel more specific biomarkers of NEPC, allowing for these biomarkers to be synergistically utilized to more accurately measure the occurrence of neuroendocrine dedifferentiation and the response of NEPC to therapy.

2. KEYWORDS

Hyperpolarized ^{13}C magnetic resonance imaging, pyruvate, lactate, metabolism, treatment emergent neuroendocrine prostate cancer, biomarkers, therapeutic resistance, castrate-resistant prostate cancer.

3. ACCOMPLISHMENTS

The major goal of Specific Aim 1: is to establish the molecular and metabolic signature of t-NEPC tumors and develop new HP ^{13}C labeled probes to identify neuroendocrine differentiation from and its response to therapy. Preliminary data and analysis towards this goal are listed below

3.1.a Hyperpolarized imaging of TRAMP mice

Aim 1 is centered around the genetically engineered mouse model of TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate), which upon treatment develops NEPC similar to the clinical setting according to the schema presented in **figure 1**. The third arm of the study (group III) was prioritized if the animal was doing well, over the other two control groups in the first set




Figure. 1: Timeline of animal model development and imaging

imaging). The squares represent hyperpolarized carbon-13 spectroscopy data from a single voxel of the TRAMP tumor from the T₂ weighted proton image. **Figure 2** clearly shows the increasing volume over the weeks with decreasing lactate signal (relative to the pyruvate). We then quantified the apparent rate of conversion of pyruvate to lactate (k_{PL}) using an input-less, single compartment modeling (Ref: Larson, P. E. Z., Chen, H.-Y., Gordon, J. W., Korn, N., Maidens, J., Arcak, M., et al. (2018). Investigation of analysis methods for hyperpolarized ^{13}C -pyruvate metabolic MRI in prostate cancer patients. *NMR in Biomedicine*, 31(11), e3997.

<http://doi.org/10.1002/nbm.3997>). **Figure 3** shows the apparent rate of conversion of pyruvate to lactate (k_{PL}) in Group III mice over time (blue- 1 week post-castration, purple – 1 week post




Figure 2. Hyperpolarized ^{13}C imaging. The top row shows the T2 weighted proton images and the bottom row shows the raw spectrum from a single voxel (green box).

ARN509, red – 2 weeks post ARN-509 and green – 1 week post carboplatin) and the corresponding change in tumor volumes. The reduction in k_{PL} with carboplatin treatment is significant and corresponds to the dramatic reduction in the tumor growth rate. Furthermore, **figure 3** also shows the decreased trend




Figure 2. The graph on the left shows the apparent rate of conversion of pyruvate to lactate (k_{PL}) in Group III mice over time. The graph on the right shows the corresponding change in tumor growth rate in the same mice.

in metabolism (reduced k_{PL}) while the tumor volume is still increasing pointing to a therapeutic response. The tumor growth rate is depicted as the change in tumor volume/day over the last week since intervention. We are currently in the process of collecting data for Group I mice to elucidate the clear treatment effect of ARN-509 and confirmation on immunohistochemical staining.

With regards to the other probes HP [$1\text{-}^{13}\text{C}$]acetate and [$2\text{-}^{13}\text{C}$]Pyruvate (in lieu of [$5\text{-}^{13}\text{C}$] glutamine per our first year findings), we have not been able to observe any metabolism, we have tried $n=3$ TRAMP mice for each group (baseline - CRPC, Group I – adenocarcinoma CRPC as well as Group II - NEPC).

3.1.b Quantification of NEPC in TRAMP tumors from immunohistochemical staining and biochemical assays on serum.

During the first year, we established a mouse serum analysis of NSE (neuron specific enolase), a marker of neuroendocrine disease (selective although not specific) and correlated it to a quantitative estimate of NEPC from immunohistochemical staining for synaptophysin and NSE. In our experience the past two years, there is significant mortality of TRAMP mice with treatment over time making a 3 week follow up after chemotherapy highly challenging. Hence the




Figure 3. Serum NSE activity. The bar graph shows the increasing trend in NSE activity in TRAMP serum with ARN509 treatment.

treatment regimen for ARN509 was reduced to 1 week in a cohort of mice. Due to the reduction in the gap between ANR509 and subsequent therapy we needed to ensure significant development of NEPC and this was preliminarily assessed using the NSE serum test as shown in **figure 4**. The initial data suggest an increasing trend of serum NSE activity and the associated tumor volumes increased during the two weeks following ARN509 treatment. Further evaluation and correlation to quantitative analysis of Synaptophysin immunohistochemical staining is under way.




Figure 5. Effect of ARN509 treatment in TRAMP mice.

There is a significant increase in tumor volume with treatment. The fractional enrichment, shows a reduction in glucose metabolism and glycolysis in the ARN509 treated TRAMP (dark gray bars) mice in comparison to the castrate resistant (light gray bars) and more similar to the castrate sensitive TRAMP (black bars).

3.1.c Metabolic profiling of TRAMP tumors

We have performed [U-¹³C]glucose labeling studies on a cohort of TRAMP mice (n=3 each) of baseline (CRPC) as well as animals treated with ARN509 for 1 week post castration. While the tumor volume increased significantly during the one week of ARN509 treatment, metabolically, the tumors reflect a response (decrease in fractional enrichment) to the 2nd line androgen deprivation treatment as shown in **figure 5**. In fact, the ARN509 treated mice (dark gray bar) show glucose metabolic profile similar to that of castrate sensitive TRAMP mice (black bars). Although the NSE serum activity is increased we are currently in the process of confirming via immunohistochemical staining if these responders to ARN509 are CRPC or have significant presence of neuroendocrine trans-differentiation. This highlights the problem of the diagnoses of NEPC and the presentation of an admixture of cells. In order to assess the basal metabolism of a purely neuroendocrine prostate cancer cell we investigated the basal metabolism of H660 a neuroendocrine immortalized prostate cancer cell line from ATCC grown in the renal capsule of an immune-compromised mouse. These results are shown in comparison to the TRAMP tissue (**figure 6**) and clearly highlights the much lower metabolism of the neuroendocrine cell line which is probably an artifact of the cell model. Alternatively, we are currently investigating, purely NEPC PDX lines that have been established by University of Washington, namely LuCaP 93.




Figure 6. Glucose flux. Flux of glucose is represented as fractional enrichment to the key metabolites. The H660 tumors (dark gray bars) show an overall reduced metabolism compared to the androgen dependent (black bar) and independent (light gray bar) TRAMP tumors.

3.2 Estimating metabolic fluxes in patient derived prostate biopsy samples

In Aim 2, we proposed to define the molecular and metabolic signature of metastatic NEPC tumors from patient biopsy samples. Therein we also proposed to quantitatively capture the spectrum of **metabolic fluxes** associated with NEPC. Such an endeavor has never been published thus far and in order to optimize the procedures, this was undertaken in primary prostate biopsies (rather than the metastatic biopsies from the WCDT cohort, which is of limited availability and shared over a large number of researchers). This has resulted in a manuscript

published in Magnetic Resonance in Medicine, and is attached (Brown, J. B., Sriram, R., VanCricking, M., Santos, R. D., Sun, J., Santos, J. D., et al. (2019). NMR quantification of lactate production and efflux and glutamate fractional enrichment in living human prostate biopsies cultured with [1,6-¹³C₂]glucose. *Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine*, 82(2), 566–576. <http://doi.org/10.1002/mrm.27739>). In, brief, we showed through this work a protocol for quantification of lactate production–efflux and TCA cycle activity in single living human prostate biopsies, allowing metabolic labeling on a wide spectrum of human tissues (e.g., metastatic, post-non-surgical therapy) from patients not receiving surgery. This work also helped determine: 1) the minimum amount of tissue that was needed (for biopsy samples) to be able to get data in a reasonable amount of time to be 3mg; 2) A core taken (using the biopsy gun) from a surgically removed prostate versus snap frozen biopsy samples which were used in this study, resulted in much larger lactate signal and very little of other metabolites and indicated severe warm ischemia; and 3) labeling/ culturing of biopsy tissue needs to be <24 hours, as long periods resulted in significant tissue degradation. NEPC biopsy tissues that we have accessed thus far have been <1mg and we have not been able to make reliable MR measurements in these tissues. We will continue to avail of the tissues and try to optimize our measurement protocol even further as well as use NEPC PDX models in order to understand glycolytic and TCA metabolic changes that occur in this very heterogeneous disease state.

Training and professional development

Fayyaz Ahamed, an undergraduate student from University of California, Berkeley, did a summer internship in our lab and worked on this project to develop an image processing pipeline to automatically quantify the immunohistochemical staining of neuroendocrine cells. Dr. Jinny Sun, a doctoral student who has been working on this project this past two years has gained professional development by attending the international conference of “international society of magnetic resonance in medicine” to give an oral presentation on the metabolomics of TRAMP tumor with treatment. And Dr. Shubhangi Agarwal, the postdoctoral fellow working on the hyperpolarized imaging has gained high impactful training on the use of this novel imaging technology. It also aided in the professional development of the Principle investigator, Dr. Renuka Sriram as she was invited to present her work from this project in the Fifth International Workshop on Metabolic Imaging.

Dissemination of results to communities of interest

Some of the initial results and metabolomics data were presented in the annual internal prostate cancer research program meeting at University of California, San Francisco. At this meeting there are patient advocates and outreach coordinators and initiative was taken to communicate to them, some of the impact of our work on future care and clinical practice.

Plan for next reporting period

In the next reporting period, we hope to complete imaging of the other arms of the study for Aim I towards imaging of the TRAMP mice as well as their metabolic analysis. And for Aim 2 access the WCDT biopsy samples under the auspices of Dr. Agarwal (the co-Pi) on this grant, for metabolic profiling using HR-MAS NMR technique and to supplement this information with NEPC PDX models.

We hope to publish the manuscript on the metabolomic profiling of the TRAMP tumors with therapy before the end of this calendar year which forms the bulk of the student’s doctoral thesis.

4. IMPACT

The biggest impact from the preliminary studies thus far in the field of imaging and prostate cancer, has been

- i. The pre-clinical model using the TRAMP mice, while invaluable for the clinically relevant progression of disease, complicates the imaging biomarker development, due to the presence of admixture of varying disease phenotypes. To overcome this, we have developed preclinical tools such as a) quantitative imaging of immunohistochemical stains of neuroendocrine cells, b) serum assays for neuron specific enolase activity, and c) correlation of the two metrics.
- ii. We have established a method feasible to keep biopsy tissue viable and measure the glycolytic process *in situ*.

There is nothing significant to report with regards to technology transfer and impact to society beyond science and technology.

5. CHANGES/PROBLEMS

It seems from our preliminary efforts, that the biopsy from patients with metastatic NEPC disease are not large enough to yield robust NMR data.

6. PRODUCTS

▪ Journal publications.

Brown JB, **Sriram R**, VanCrieking M, Santos RD, Sun J, Santos JD, et al. (2019). NMR quantification of lactate production and efflux and glutamate fractional enrichment in living human prostate biopsies cultured with [1,6-¹³C₂]glucose. *Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine*, 82(2), 566–576. <http://doi.org/10.1002/mrm.27739>

▪ Conference and presentations

"Development of Hyperpolarized ¹³C metabolic biomarkers of prostate cancer aggressiveness - from cells to patient derived tissues". The Fifth International Workshop on Metabolic Imaging, University of Pennsylvania, PA, USA.

Sun J, Delos Santos J, Bok R, Delos Santos R, Van Crieking M, Vigneron DB, **Sriram R**, Kurhanewicz J. "Androgen Independence Leads to Altered Metabolism in Prostate Cancer Cell and Murine Models". Oral Presentation at the annual meeting of International Society of Magnetic Resonance in Medicine, 2019, Montreal, Canada.

7. PARTICIPANTS

Name:	<i>Renuka Sriram</i>
Project Role:	<i>PI</i>
Researcher Identifier (e.g. ORCID ID):	0000-0003-3505-2479
Nearest person month worked:	<i>4</i>
Contribution to Project:	<i>Hypothesis development, Experimental design, Data acquisition and analysis.</i>
Funding Support:	

Name:	<i>John Kurhanewicz</i>
-------	-------------------------

Project Role:	<i>Co-I and mentor</i>
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	<i>1</i>
Contribution to Project:	<i>Guidance on hyperpolarized experiments and data interpretation.</i>
Funding Support:	

Name:	<i>Rahul Aggarwal</i>
Project Role:	<i>Co-I</i>
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	<i>1</i>
Contribution to Project:	<i>Biopsy tissue acquisition and genetic analysis</i>
Funding Support:	

Name:	<i>Jinny Sun</i>
Project Role:	<i>Graduate student</i>
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	<i>12</i>
Contribution to Project:	<i>Metabolomics</i>
Funding Support:	<i>Graduate program</i>

Name:	<i>Shubhangi Aggarwal</i>
Project Role:	<i>Postdoctoral Scholar</i>
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	<i>6</i>
Contribution to Project:	<i>Hyperpolarized TRAMP imaging studies – data acquisition and analysis</i>
Funding Support:	

Name:	<i>Robert Bok</i>
Project Role:	<i>Animal model expert</i>
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	<i>1</i>
Contribution to Project:	<i>Animal model handling and IHC stain interpretation</i>
Funding Support:	

Name:	<i>Romelynn DeLos Santos</i>
Project Role:	<i>Lab manager</i>
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	<i>1</i>
Contribution to Project:	<i>Tissue repository as well as IHC staining</i>
Funding Support:	

Name:	<i>Fayyaz Ahamed</i>
Project Role:	<i>Summer intern</i>
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	<i>1</i>
Contribution to Project:	<i>IHC quantification</i>
Funding Support:	

- **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

"Nothing to Report."

- **What other organizations were involved as partners?**

"Nothing to Report."

NMR quantification of lactate production and efflux and glutamate fractional enrichment in living human prostate biopsies cultured with [1,6-¹³C₂]glucose

Jeremy Bancroft Brown¹  | Renuka Sriram¹ | Mark VanCrieke¹ |
Romelyn Delos Santos¹ | Jinny Sun¹ | Justin Delos Santos¹ | Z. Laura Tabatabai² |
Katsuto Shinohara³ | Hao Nguyen³ | Donna M. Peehl¹ | John Kurhanewicz¹

¹Department of Radiology and Biomedical Imaging, University of California, San Francisco, California

²Department of Anatomic Pathology, University of California, San Francisco, California

³Department of Urology, University of California, San Francisco, California

Correspondence

John Kurhanewicz, University of California, San Francisco, Byers Hall, Room 203E, 1700 4th Street, Box 2520, San Francisco, CA 94158.
Email: john.kurhanewicz@radiology.ucsf.edu

Funding information

National Cancer Institute, Grant/Award Number: 5R01CA215694; National Institute of Biomedical Imaging and Bioengineering - P41 EB013598; Department of Defense - W81XWH-17-1-0471.

Purpose: Image-guided prostate biopsies are routinely acquired in the diagnosis and treatment monitoring of prostate cancer, yielding useful tissue for identifying metabolic biomarkers and therapeutic targets. We developed an optimized biopsy tissue culture protocol in combination with [1,6-¹³C₂]glucose labeling and quantitative high-resolution NMR to measure glycolysis and tricarboxylic acid (TCA) cycle activity in freshly acquired living human prostate biopsies.

Methods: We acquired 34 MRI-ultrasound fusion-guided prostate biopsies in vials on ice from 22 previously untreated patients. Within 15 min, biopsies were transferred to rotary tissue culture in 37°C prostate medium containing [1,6-¹³C₂]glucose. Following 24 h of culture, tissue lactate and glutamate pool sizes and fractional enrichments were quantified using quantitative ¹H high resolution magic angle spinning Carr-Purcell-Meiboom-Gill (CPMG) spectroscopy at 1°C with and without ¹³C decoupling. Lactate effluxed from the biopsy tissue was quantified in the culture medium using quantitative solution-state high-resolution NMR.

Results: Lactate concentration in low-grade cancer (1.15 ± 0.78 nmol/mg) and benign (0.74 ± 0.15 nmol/mg) biopsies agreed with prior published measurements of snap-frozen biopsies. There was substantial fractional enrichment of [3-¹³C]lactate (≈70%) and [4-¹³C]glutamate (≈24%) in both low-grade cancer and benign biopsies. Although a significant difference in tissue [3-¹³C]lactate fractional enrichment was not observed, lactate efflux was significantly higher (*P* < 0.05) in low-grade cancer biopsies (0.55 ± 0.14 nmol/min/mg) versus benign biopsies (0.31 ± 0.04 nmol/min/mg).

Conclusion: A protocol was developed for quantification of lactate production–efflux and TCA cycle activity in single living human prostate biopsies, allowing metabolic labeling on a wide spectrum of human tissues (e.g., metastatic, post-non-surgical therapy) from patients not receiving surgery.

KEYWORDS

biopsy, efflux, lactate, metabolism, prostate, tracer

1 | INTRODUCTION

Prostate cancer metabolism is characterized by a shift to aerobic glycolysis and lactate production, known as the Warburg effect.¹⁻⁵ Yet, it is not currently known how tumor metabolism changes in the setting of human castration-resistant and/or neuroendocrine prostate cancer (CRPC/NEPC). Recent studies have identified genetic alterations with significant putative metabolic effects in human CRPC.^{6,7} To investigate these effects, it is essential to measure metabolism in living human prostate tissue. Our laboratory has previously used an optimized rotary tissue culture system to perform ¹³C NMR metabolic labeling studies in slices of human prostate tissue acquired from radical prostatectomy (RP).⁸⁻¹⁰ Yet, RP is not standard of care for CRPC or NEPC, so the tissue slice technique cannot be applied in this clinically significant cohort of patients to yield a better insight into their respective metabolic adaptations. Although it is clinically feasible to obtain biopsy samples from patients with CRPC and/or NEPC, a novel metabolic profiling protocol that is optimized for living human biopsies is needed to study these specimens.

In the current work, we demonstrate that the combination of rotary biopsy culture, ¹³C metabolic labeling, and NMR can quantify metabolism in freshly acquired living human prostate biopsies. The current research focuses on the development of the techniques necessary to acquire and measure the Warburg effect in living patient-derived biopsies, acquired before treatment for the determination of cancer presence, Gleason grade, and extent for personalized therapeutic selection. By definition, this was an early stage cancer patient population, resulting in the acquisition of mainly benign and low grade (primary Gleason pattern 3) prostate cancer biopsies in this study. However, the ultimate goal is to use the optimized techniques developed in this study to assess the Warburg effect and other changes in metabolism in biopsies from patients with advanced disease who would not normally receive surgical therapy.

A particular motivation for studying the metabolism of prostate cancer comes from the preclinical and clinical development of hyperpolarized ¹³C MRI techniques,¹¹⁻¹⁴ with clinical trials of hyperpolarized [1-¹³C]pyruvate in prostate cancer now underway at multiple sites.¹⁵ In prostate cancer, there is considerable heterogeneity of prognosis for patients, particularly for those with a cancer of Gleason 7 histopathological score or lower.¹⁶ Therefore, there is significant potential for hyperpolarized ¹³C metabolic imaging of primary prostate cancer to provide additional information to the clinician, in combination with Gleason scoring and clinical risk

scores such as the Cancer of the Prostate Risk Assessment (CAPRA) score.¹⁷ In the metastatic setting, it is widely recognized that metabolic responses to therapy can significantly precede anatomic responses,¹⁸ which means that hyperpolarized ¹³C metabolic imaging may be able to better inform in real-time spatially resolved treatment monitoring for the clinician and patient in conjunction with serum tumor markers such as prostate-specific antigen (PSA).¹⁹

In hyperpolarized ¹³C MRI, the measured signal is proportional to the product of (1) probe polarization, (2) the fractional enrichment of the precursor being converted to the produced metabolite, and (3) the pool size of the produced metabolite.²⁰ In the ex vivo setting, it becomes possible to disentangle these factors, ideally leading to a better interpretation and understanding of the hyperpolarized ¹³C signal¹⁰ and enabling the development of new hyperpolarized probes and potential therapeutic targets.

A significant challenge in the metabolic profiling of specific biochemical pathways using stable isotopes in individual living prostate biopsies by NMR is the small tissue mass ranging from 1–6 mg, which limits the achievable SNR. Therefore, in the present work, we have focused on optimizing the experimental parameters such as the duration of time in rotary biopsy culture and the parameters of the NMR acquisition so as to achieve sufficient metabolite signals from a small mass of tissue incubated with ¹³C-labeled metabolic substrates.

2 | METHODS

2.1 | Biopsy acquisition

Transrectal 18-gauge prostate biopsies from 22 previously untreated patients (34 total biopsies, 27 normal prostate biopsies, 5 Gleason 6(3+3) cancer biopsies, and 2 Gleason 7(3+4) cancer biopsies) were acquired with Institutional Review Board approval. Biopsies were acquired using an ultrasound-MRI fusion system that provided registration of transrectal ultrasound images to prior prostate MRI (UroNav, InVivo, Gainesville, FL). The clinical efficacy of this system has been evaluated previously.²¹ Up to 2 research biopsies per patient were acquired from any visible multiparametric ¹H MRI or ultrasound lesions once the clinical biopsy acquisition had been completed. In cases with fewer than 2 visible lesions, a biopsy was sometimes taken from a normal-appearing area of the peripheral zone. Immediately following acquisition, biopsies were stored in vials on ice and were transferred to rotary culture within 15 min.

2.2 | Biopsy culture medium

A formulation of PFMR-4A medium with supplements optimized for prostate tissue culture was previously described.^{8,9} For this study, it was found that HEPES and threonine in this medium posed a potential challenge for the quantification of NMR spectra. Consequently, we developed a formulation of bicarbonate-buffered, HEPES-free, threonine-free, pyruvate-free F-12 medium containing all of the previously described supplements.^{8,9} (The complete medium recipe is provided in Supporting Information Tables S1 and S2). For labeling studies, the medium contained exclusively [1,6-¹³C₂]glucose at 1.0 g/L.

2.3 | Biopsy rotary tissue culture

Techniques previously described for the culture of thin, precision-cut prostate tissue slices⁸ were adapted for culture of biopsies. Each biopsy was loaded onto a titanium mesh inside of 1 well of a 6-well plate containing 2.5 mL per well

of pre-warmed F-12 prostate medium with [1,6-¹³C₂]glucose. The plates were loaded onto a rotary tissue culture system (Alabama R&D) (Figure 1B) within a 37°C, 5% CO₂ incubator, and the biopsies were cultured for either 24 or 26 h. For a subset of samples, the biopsy culture medium was collected and replaced with fresh pre-warmed medium at the 2-h time point to quantify the initial rate of lactate efflux, in addition to the lactate efflux after 24 h of culture. Each 6-well plate also contained a control well containing medium but without any biopsy tissue. At the end of the culture period, the medium was collected and stored at -80°C.

2.4 | Biopsy rinsing

After culture, the biopsies were placed in ice-cold phosphate-buffered saline for <1 min, blotted with a delicate task wipe, and stored at -80°C. This procedure was intended to remove medium that could otherwise contaminate the




FIGURE 1 Study protocol. (A) MRI fusion biopsy was followed by (B) rotary tissue culture with [1,6-¹³C₂]glucose. (C) Tissue lactate and (D) glutamate concentration and fractional enrichment were quantified using HR-MAS of biopsy samples, whereas (E) lactate efflux in media was quantified using NMR. (F) The biopsy histopathology was obtained after culture

post-culture biopsy high resolution-magic angle spinning (HR-MAS) NMR spectra as we have shown previously.²²

2.5 | Biopsy tissue NMR measurements

Frozen biopsies were loaded without thawing into a sealed zirconium HR-MAS rotor^{22,23} on a tared digital balance to measure the wet weight of the biopsy tissue. Six μL of $\text{D}_2\text{O}/0.05\%$ trimethylsilylpropanoic acid (TSP) solution was further added to the rotor and weighed to enable deuterium locking as well as a chemical shift reference via TSP. The HR-MAS rotor was sealed and loaded into a 500 MHz Varian gHX Nano (proton-carbon double resonance) 4 mm indirect detection HR-MAS probe maintained at 1°C . Acquisition was performed at a spin rate of 2.25 kHz using a Varian Inova console with VNMRJ 4 after locking on the D_2O signal. The probe tuning, 90° pulse width and water saturation frequency were calibrated for each sample. Each sample was shimmed using an automated FID shimming routine for 20 min (see Supplemental Information). ^1H Carr-Purcell-Meiboom-Gill (CPMG) spectra were acquired with 60,000 complex points, 3-s acquisition time, 2-s water suppression pulse, 6-s overall repetition time, and 1024 scans. It was previously established that this repetition time yielded fully relaxed spectra in human prostate tissue.²⁴ The CPMG TE was set to 288 ms. The spacings of 180° pulses within the CPMG sequence were synchronized to the spinning period of the rotor.²⁴ To quantify metabolite total pools in addition to ^{13}C -labeled fractions, CPMG data sets were acquired both with and without heteronuclear ^{13}C decoupling using a GARP pulse^{22,25} for a total CPMG scan time of 3 h, 25 min.

2.6 | Biopsy histopathology

Following the HR-MAS data acquisition, the biopsies were fixed in 10% neutral-buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) and high-molecular weight cytokeratin for interpretation by a board-certified genitourinary pathologist. For each sample the pathologist determined the primary Gleason pattern, secondary Gleason pattern, Gleason score, percentage of cancer, percentage of glandular tissue, and percentage of stromal tissue.

2.7 | Biopsy media NMR measurements

The samples of biopsy medium were thawed from storage at -80°C . NMR samples were prepared by adding 65 mg of $\text{D}_2\text{O}/0.05\%$ TSP to 540 mg of conditioned medium and placed in 5 mm NMR tubes. The sample data were acquired at 600 MHz using a Bruker Avance III console equipped with a 5 mm Bruker BBFO (broadband double resonance) direct detection probe. The 90° pulse was calibrated, and automated z-axis shimming was performed up to 8th order in addition

to tuning of all first-order shims (see Supporting Information Tables S3 and S4). Water-suppressed data were acquired using a fully relaxed ZGCPPR pulse sequence with a 12-s acquisition time (114,942 points) and 3-s relaxation delay and 32 scans (8 min per sample).

2.8 | NMR data processing

All NMR data sets were processed in MestreNova 12 (Mestrelab Research S.L.). The data sets were zero-padded by a factor of 2, apodized with a 0.25 Hz exponential filter, and automatically phased and baselined using a Whittaker smoother algorithm²⁶ and manually adjusted as needed. Peaks of interest were automatically picked and fitted using a Lorentzian-Gaussian shape function with a simulated annealing algorithm (500 coarse iterations, 100 fine iterations, and a local minima filter of 25 were used). All automated peak fits were tweaked after visual assessment for fit quality based on the residual signal and adjusted when necessary.

2.9 | NMR quantification

In the biopsy HR-MAS CPMG data, peak areas were quantified relative to the calibrated amplitude of the electronic reference to access in vivo concentrations (ERETIC) signal, corrected for the number of metabolite protons.²³ Appropriate T_2 corrections were applied based on HR-MAS measurements in human prostate tissue at 1°C and 500 MHz (lactate C3 $T_2 = 251$ ms, glutamate C4 $T_2 = 275$ ms).^{4,10} Metabolite amounts were further standardized by the wet tissue weight of the sample, measured after culture, to yield a biopsy metabolite concentration in (nmol/mg). Fractional enrichments were computed as follows.

The glutamate fractional enrichment at the 4-position was computed by differencing the quantification of the 2.34 ppm C4 multiplet in the ^{13}C decoupled versus non-decoupled CPMG spectrum. This obviated the need to quantify the [4- ^{13}C]glutamate satellite peaks, which are known to underlie other peaks such as the [4- ^{12}C]glutamine peak and additionally could be further split by the presence of [3- ^{13}C]glutamate labeling on the same molecule (Figure 1D).

In the fully relaxed media data, the lactate peak area was quantified relative to the known peak area and measured mass of TSP and corrected for the relative number of protons. The lactate amount was further standardized by the wet tissue weight of the biopsy, as well as the duration of the biopsy tissue culture, to yield a lactate efflux rate in (nmol/min)/(mg tissue).

2.10 | LIVE/DEAD assays and imaging

At the end of the culture experiment, a limited number of biopsies were transferred to a new well containing medium

with ethidium homodimer-1 at 0.5 $\mu\text{mol/L}$ and calcein-AM at 2.5 $\mu\text{mol/L}$.²⁷ The biopsies were maintained in culture for a further 2 h and then rinsed for 10 min in phosphate-buffered saline under dark conditions before blotting with a delicate task wipe and imaging on a laser scanning confocal microscope (Zeiss 780). A two-photon excitation was used at a 759 nm wavelength with a $25\times$ water immersion objective, a 1024×1024 image size, and 2 averages. The detection windows were set as 493–556 nm for green and 615–741 nm for red. Z-stack images were acquired using overlapping optical sectioning with thickness determined by 1 Airy unit, with the maximum possible Z-stack height to assess tissue viability throughout the sample. We found that our extended staining protocol allowed the stain to diffuse throughout the biopsy, which made it possible to acquire a Z-stack covering the entire biopsy thickness ($\sim 400\ \mu\text{m}$). Because of the time spent at room temperature on the microscope, the samples analyzed in this manner were not used for any HR-MAS data acquisition after imaging.

3 | RESULTS

3.1 | Overview of study protocol

The MRI fusion biopsy procedure provided registration of ultrasound to multiparametric prostate MRI, with the MRI lesion highlighted for biopsy targeting (Figure 1A). The freshly acquired biopsies were cultured with $[1,6-^{13}\text{C}]$ glucose that was converted into $[3-^{13}\text{C}]$ pyruvate via glycolysis (Figure 1B). The pyruvate interconverted with the intracellular lactate pool, which was quantified after culture using HR-MAS. In Figure 1C, the 500 MHz HR-MAS spectrum shows doublets of $[3-^{12}\text{C}]$ alanine, $[3-^{13}\text{C}]$ lactate, and $[3-^{12}\text{C}]$ lactate going from left to right (total scan time for this spectrum: 1 h, 42 min). The pyruvate also entered the TCA cycle via pyruvate dehydrogenase, which led to labeling at the 4-position of α -ketoglutarate following 1 turn of the cycle. This interconverted with glutamate to produce labeling at the 4-position of glutamate. Figure 1D shows the higher amplitude of the multiplets corresponding to the C4 protons of glutamate when decoupling is turned on (total scan time for this spectrum, with decoupling both off and on: 3 h, 25 min). Figure 1E shows a representative spectrum of the medium signifying the efflux of lactate and alanine from the biopsy tissue as evidenced by the ^{13}C satellite peaks of the respective methyl protons. The biopsy histopathology after culture demonstrated well-defined glands with preserved tissue microarchitecture (Figure 1F: H&E staining, $20\times$ magnification). The representative biopsy was benign with 30% glandular tissue and 70% stromal tissue (a detail of a glandular region is shown).

3.2 | Study data set

We obtained a total of 34 biopsies from 22 previously untreated patients. Of these biopsies, 16 were targeted to a radiologist-identified MRI lesion using the MRI-ultrasound fusion biopsy device. Twenty-seven benign biopsies and 7 cancer biopsies were acquired. The mean $\pm$ SE wet tissue weights were 3.65 ± 0.28 mg for benign biopsies and 4.40 ± 0.49 mg for cancer biopsies. Among the benign biopsies, the average percentage of benign glandular tissue was 17% as determined by a board-certified genitourinary pathologist. Of the 7 cancer biopsies, 5 had a Gleason score of 6(3 + 3) and 2 had a Gleason score of 7(3 + 4). The average percentage of cancer within the cancer biopsies was 12%, and the average percentage of benign glandular tissue was 9%. Of the 7 cancer biopsies, 4 were acquired from MRI-fusion targeted regions and 3 were acquired from non-MRI targeted regions.

3.3 | Biopsy media NMR measurements

We observed considerable efflux of $[3-^{13}\text{C}]$ lactate into the medium during culture. In the representative NMR spectra normalized to tissue mass shown in Figure 2A, the cancer (yellow) medium after 24 h of culture demonstrated a higher level of $[3-^{13}\text{C}]$ lactate efflux compared to the benign (blue) medium.

As shown in Figure 2B, benign biopsies had a $[3-^{13}\text{C}]$ lactate efflux rate of 0.29 ± 0.04 nmol/min/mg (mean $\pm$ SE), whereas cancer biopsies had a $[3-^{13}\text{C}]$ lactate efflux rate of 0.52 ± 0.14 nmol/min/mg measured over 24 h in culture. Benign biopsies had a total lactate efflux rate of 0.31 ± 0.04 nmol/min/mg (mean $\pm$ SE), whereas cancer biopsies had a total lactate efflux rate of 0.55 ± 0.14 nmol/min/mg measured over 24 h in culture. Both the $3-^{13}\text{C}$ and total lactate efflux rates were significantly higher for the cancer biopsies ($P < 0.05$, two-tailed Student's t-test for independent samples). The fractional enrichment of the effluxed lactate was $95 \pm 1\%$ for benign biopsies and $94 \pm 1\%$ for cancer biopsies, with no significant fractional enrichment differences observed between benign and cancer biopsies.

In an effort to assess the stability of lactate efflux over time in culture, for the majority of biopsies the lactate efflux rate per minute was measured from media collected after 2 h of biopsy culture ("0–2 h") and again from media collected after a further 24 h of biopsy culture ("2–26 h"). We did not observe significant differences between the lactate efflux rates measured over these 2 time points (Figure 3A: benign 0–2 h: 0.33 ± 0.05 nmol/min/mg, benign 2–26 h: 0.28 ± 0.03 nmol/min/mg; and 3B: cancer 0–2 h: 0.49 ± 0.10 nmol/min/mg, cancer 2–26 h: 0.53 ± 0.23 nmol/min/mg).




FIGURE 2 Biopsy lactate efflux and concentration. (A) Representative NMR spectra from benign (blue) and cancer (yellow) media. The broad peak that is superimposed with the $3\text{-}^{12}\text{C}$ lactate doublet at 1.33 ppm is a medium additive that was deconvolved during the quantification process. (B) Quantification of [$3\text{-}^{13}\text{C}$]lactate efflux and total lactate efflux in media. There was significantly greater [$3\text{-}^{13}\text{C}$]lactate and total lactate efflux in cancer biopsies compared to benign biopsies ($P < 0.05$)




FIGURE 3 Biopsy lactate efflux over time. The biopsy lactate efflux rate per minute was measured from media collected after 2 h in culture (“0–2 h”) and again collected after a further 24 h in culture with the same biopsy (“2–26 h”)

3.4 | Biopsy tissue NMR measurements

Of the 34 biopsies cultured during this study, 7 were used for non-HR-MAS experiments after culture and 6 were not measured by HR-MAS because of technical issues. We obtained high-quality HR-MAS data from 21 biopsies suitable for metabolite quantification. Of these HR-MAS samples, 16 were benign, 4 were Gleason score 6(3 + 3), and 1 was Gleason score 7(3 + 4). It was possible to observe a number of metabolites in the HR-MAS CPMG spectra from biopsy tissues after culture, including metabolites that we have previously quantified in prostate tissue such as phospholipids²⁸ (Figure 4A). However, the focus of the present study was lactate production and efflux in culture. Despite a trend

toward higher lactate levels in the cancer biopsies, we did not observe significant differences between benign and cancer biopsies after culture (Figure 4B). The [$3\text{-}^{13}\text{C}$]lactate concentration after culture was 0.56 ± 0.12 nmol/mg (mean $\pm$ SE) in benign biopsies and 0.73 ± 0.49 nmol/mg in cancer biopsies. The total lactate concentration after culture was 0.74 ± 0.15 nmol/mg (mean $\pm$ SE) in benign biopsies and 1.15 ± 0.78 nmol/mg in cancer biopsies. The fractional enrichment was $72 \pm 6\%$ in benign biopsies and $71 \pm 6\%$ in cancer biopsies.

3.5 | Labeling of glutamate from [$1,6\text{-}^{13}\text{C}_2$] glucose

We were able to detect an increase of the glutamate C4 multiplet amplitude at 2.34 ppm with ^{13}C decoupling turned on, indicating fractional enrichment (representative spectrum, Figure 5A). However, no significant differences were observed between the benign and cancer (primary pattern 3) biopsies in terms of the glutamate concentration and/or fractional enrichment (Figure 5B). As shown in Figure 5B, the [$4\text{-}^{13}\text{C}$]glutamate concentration after culture was 0.32 ± 0.10 nmol/mg (mean $\pm$ SE) in benign biopsies and 0.27 ± 0.15 nmol/mg in cancer biopsies. The total glutamate concentration after culture was 1.18 ± 0.23 nmol/mg in benign biopsies and 0.92 ± 0.47 nmol/mg in cancer biopsies. The fractional enrichment of C4 glutamate after culture was $24 \pm 3\%$ in benign biopsies and $24 \pm 7\%$ in cancer biopsies.

3.6 | Biopsy LIVE/DEAD staining

We assessed the biopsy viability after 26 h in rotary culture using a fluorescent vital stain that is trapped in living cells (Calcein-AM) combined with a nuclear stain that enters




FIGURE 4 Biopsy tissue HR-MAS spectra. (A) Examples of CPMG spectra from benign (blue) and cancer (yellow) samples after culture. The [2-¹²C]lactate peak is visible at left, as a quartet split by the long-range coupling (~4 Hz) to [3-¹³C]lactate. Ala, alanine; Glu, glutamate; Gln, glutamine; GSH, glutathione; Cre, creatine; Cho, choline; PC, phosphocholine; GPC, glycerophosphocholine; ml, myo-inositol; sl, scyllo-inositol. (B) Quantified CPMG data: [3-¹³C]lactate concentration, total lactate concentration and fractional enrichment of lactate at the 3-position

the nuclei of dead cells (ethidium homodimer-1). Scattered cells demonstrated staining with ethidium homodimer-1, but the biopsies were primarily stained by the calcein-AM (Figure 6A), indicating that the majority of cells remained viable in biopsies after culture. The corresponding histopathology slides further demonstrated intact glandular architecture after culture (Figure 6B).

4 | DISCUSSION

In this study, we found that it was possible to perform NMR measurements of metabolism in individual living human prostate biopsies. Furthermore, the ¹³C-labeled and overall rates of lactate efflux in culture were significantly higher for low-grade (primary Gleason pattern 3) cancer biopsies as

compared to benign biopsies (Figure 2). In the HR-MAS data (Figure 4), for benign biopsies, we observed a tissue lactate concentration of 0.74 ± 0.15 nmol/mg, in good agreement with a prior published measurement of 0.61 ± 0.28 nmol/mg in snap-frozen biopsy samples by Tessem et al.⁴ For cancer biopsies, we observed a tissue lactate concentration of 1.15 ± 0.78 nmol/mg, as compared to a prior measurement of 1.59 ± 0.61 nmol/mg in snap-frozen cancer biopsies.⁴ This discrepancy can perhaps be explained by the fact that the present data set contained only low-grade prostate cancer biopsies (primary Gleason pattern 3), whereas the data set from Tessem et al.⁴ contained specimens of low- and high-grade prostate cancer (primary Gleason patterns 3 and 4). These findings are consistent with the notion that there is a more pronounced Warburg effect in high-grade prostate cancer such as primary Gleason pattern 4.²⁹





FIGURE 6 Biopsy LIVE/DEAD staining. (A) Confocal 2-photon microscopy from biopsy samples stained with calcein-AM and ethidium homodimer-1 following 26 h in culture. (B) Biopsy histopathology obtained after confocal microscopy. Each hematoxylin and eosin (H&E) stained image originates from the same sample as the confocal image directly above but not from the exact same location in the tissue

Interestingly, although a significant difference in tissue lactate fractional enrichment coming from $[1,6\text{-}^{13}\text{C}_2]\text{glucose}$ was not observed, the overall rate of lactate efflux in culture was significantly higher for primary Gleason pattern 3

cancer biopsies as compared to benign biopsies. This was presumably because of not only the trend toward higher lactate pool size (Figure 4), but also the propensity of the cancer tissue to export the lactate (Figure 2). This is consistent with prior data showing overexpression of the lactate dehydrogenase-A (LDHA) isoform (favoring lactate production from pyruvate) as well as overexpression of the monocarboxylate transporter MCT4, favoring lactate efflux, in human prostate cancer tissue compared to benign prostatic tissue.¹⁰ Moreover, prior studies have shown that both increasing expression of MCT4 mRNA as well as MCT4 protein (quantified via immunohistochemistry) correlate with higher Gleason score, suggesting that lactate efflux from prostate biopsies would provide a sensitive assessment of aggressive disease.³⁰⁻³³

In this study, a longer duration of $[1,6\text{-}^{13}\text{C}_2]\text{glucose}$ labeling was used in culture to yield a medium $[3\text{-}^{13}\text{C}]\text{lactate}$ peak with higher SNR. It was therefore important to demonstrate that the rate of lactate efflux did not change over time, and in this study the lactate efflux rate was not significantly different at late (2–26 h) versus early (0–2 h) time points (Figure 3). Theoretically, it would also be possible to increase the lactate concentration (and hence lactate SNR) effluxed into the media by decreasing the medium volume that is used during culture. However, we used a rotary tissue culture system that relies on a 2.5 mL medium volume within a 6-well plate to provide optimal exposure to medium and 5% $\text{CO}_2/21\% \text{O}_2$ air. In our experience (data not shown), alternatives such as 24-well plates do not yield the same level of tissue viability and would need to be further optimized to provide the correct ratio of medium to air exposure over time. It is also

possible to increase the SNR of dilute NMR metabolites via lyophilization³⁴; however, using the presented protocol, we achieved sufficient media lactate SNR without additional sample processing.

The fractional enrichment of C4 glutamate coming from [1,6-¹³C₂]glucose in the biopsies studied is an indication of TCA cycle activity during rotary biopsy culture (Figures 1 and 5). In the current work, we obtained a C4 glutamate fractional enrichment of 24%. This value should be viewed as a balance between TCA cycle metabolism of [1,6-¹³C₂]glucose as well as uptake of compounds that can contribute to the unlabeled tissue glutamate pool such as glutamine and glutamate. The culture medium used for this study contained 1 mM glutamine and 0.1 mM glutamate (Supporting Information).

In this study, the biopsy metabolite levels and lactate efflux rates were normalized to wet tissue weight, which could be suboptimal in studies of highly cellular tumors. In our data set, we observed a range of tissue cellularity for both benign samples (Figures 1F and 6, left) and cancer samples (Figure 6, right). As determined by a board-certified genitourinary pathologist, in benign samples, the average percentage of glandular tissue was 17%, whereas in cancer samples, the average percentage of glandular tissue was 9%, and the average percentage of cancer was 12%. In future studies with a higher number of samples, we intend to fit a multivariate model of lactate production as a function of the predictor variables of cancer percentage and benign glandular percentage.

The choice of an appropriate metabolite normalization standard is an ongoing challenge in metabolic studies of heterogeneous tissues, as opposed to cells. In studies of cultured cells, it is common to normalize metabolites to the number of cells or to a metric of cell mass such as total protein. In tissues, automated cell counting and/or protein quantification requires tissue digestion, making it impossible to obtain high-quality histopathology. It is possible to estimate tissue cellularity using automated image analysis of histopathology slides³⁵; however, given the heterogeneity of human prostate tissue, this approach might yield inaccurate results unless the fixed, embedded, and stained tissue is comprehensively sliced to yield a 3D image stack. Another possibility is to analyze the metabolites of interest in terms of their ratios to a reference metabolite.^{10,36,37} This can be a robust method, but it does yield a metric that is sensitive to the reference metabolite as well as the metabolite of interest. Therefore, each normalization technique has strengths and limitations to practical implementation.

This study had a number of limitations. Our goal was to develop the biopsy culturing and metabolic profiling protocol, so we focused on biopsies routinely acquired from patients undergoing active surveillance or workup for prostate-related symptoms who had not been previously treated. Because of the low prevalence of aggressive cancer in this population, we only obtained biopsies containing benign

glands or primary Gleason pattern 3 cancer, which limited our ability to further characterize the metabolic phenotype of aggressive prostate cancer.

5 | CONCLUSION

In summary, a protocol was developed that allowed the quantification of lactate production and efflux in single living human prostate biopsies (1–6 mg of tissue), as well as the potential to quantify TCA metabolism through the quantification of fractional enrichment of glutamate. This was accomplished by optimizing experimental parameters such as the duration of time in rotary tissue culture (24 h) and the parameters of the NMR acquisition to achieve sufficient SNR from small metabolite signals within a 3 h and 25 min HR-MAS acquisition time. Validation studies demonstrated that this optimized protocol provided measurements of lactate production and/or fractional enrichment and efflux consistent with prior data describing lactate pool size, LDHA, and MCT4 expression in benign human prostatic tissue versus prostate cancer.^{4,10} Having established this protocol, similar measurements can then be performed on treatment-resistant and/or metastatic prostate cancer biopsies for a better understanding of metabolic perturbations in the setting of aggressive prostate cancer.

ACKNOWLEDGMENTS

The authors wish to thank Rosalie Nolley of Stanford University for preparing components of the culture medium and Professor Matthew Merritt of the University of Florida for useful discussions. Additionally, we wish to thank the MRI technologists and nursing staff of our institution as well as the patients who donated their tissue for this study.

ORCID

Jeremy Bancroft Brown  <https://orcid.org/0000-0002-2537-9059>

REFERENCES

1. Warburg O, Posener K, Negelein E. Über den stoffwechsel der carcinomzelle. *Biochem Zeitschr.* 1924;152:309–344.
2. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. *Nat Rev Cancer.* 2011;11:325–337.
3. Ros S, Santos CR, Moco S, et al. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. *Cancer Discov.* 2012;2:328–343.
4. Tessem MB, Swanson MG, Keshari KR, et al. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using

- 1H HR-MAS spectroscopy of biopsy tissues. *Magn Reson Med*. 2008;60:510–516.
5. Kurhanewicz J, Vigneron DB, Brindle K, et al. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. *Neoplasia*. 2011;13:81–97.
6. Robinson D, Van Allen E, Wu Y-M, et al. Integrative clinical genomics of advanced prostate cancer. *Cell*. 2015;161:1215–1228.
7. Quigley DA, Dang HX, Zhao SG, et al. Genomic hallmarks and structural variation in metastatic prostate cancer. *Cell*. 2018;174(758–769):e9.
8. Maund SL, Nolley R, Peehl DM. Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate. *Lab Invest*. 2013;94:208–221.
9. Peehl DM, Stamey TA. Growth responses of normal, benign hyperplastic, and malignant human prostatic epithelial cells in vitro to cholera toxin, pituitary extract, and hydrocortisone. *Prostate*. 1986;8:51–61.
10. Keshari KR, Sriram R, VanCricking M, et al. Metabolic reprogramming and validation of hyperpolarized ¹³C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. *Prostate*. 2013;73:1171–1181.
11. Chen AP, Albers MJ, Cunningham CH, et al. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T—initial experience. *Magn Reson Med*. 2007;58:1099–1106.
12. Larson PEZ, Kerr AB, Chen AP, et al. Multiband excitation pulses for hyperpolarized ¹³C dynamic chemical-shift imaging. *J Magn Reson*. 2008;194:121–127.
13. Albers MJ, Bok R, Chen AP, et al. Hyperpolarized ¹³C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. *Cancer Res*. 2008;68:8607–8615.
14. Larson PEZ, Hu S, Lustig M, et al. Fast dynamic 3D MR spectroscopic imaging with compressed sensing and multiband excitation pulses for hyperpolarized ¹³C studies. *Magn Reson Med*. 2011;65:610–619.
15. Nelson SJ, Kurhanewicz J, Vigneron DB, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. *Sci Transl Med*. 2013;5:198ra108–198ra108.
16. Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. *Eur Urol*. 2014;66:550–560.
17. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. *J Urol*. 2005;173:1938–1942.
18. Day SE, Kettunen MI, Gallagher FA, et al. Detecting tumor response to treatment using hyperpolarized ¹³C magnetic resonance imaging and spectroscopy. 2007;13:1382–1387.
19. Aggarwal R, Vigneron DB, Kurhanewicz J. Hyperpolarized 1-[¹³C]-pyruvate magnetic resonance imaging detects an early metabolic response to androgen ablation therapy in prostate cancer. *Eur Urol*. 2017;72:1028–1029.
20. Comment A, Merritt ME. Hyperpolarized magnetic resonance as a sensitive detector of metabolic function. *Biochemistry*. 2014;53:7333–7357.
21. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. *JAMA*. 2015;313:390–397.
22. Levin YS, Albers MJ, Butler TN, Spielman D, Peehl DM, Kurhanewicz J. Methods for metabolic evaluation of prostate cancer cells using proton and ¹³C HR-MAS spectroscopy and [3-¹³C] pyruvate as a metabolic substrate. *Magn Reson Med*. 2009;62:1091–1098.
23. Albers MJ, Butler TN, Rahwa I, et al. Evaluation of the ERETIC method as an improved quantitative reference for 1H HR-MAS spectroscopy of prostate tissue. *Magn Reson Med*. 2009;61:525–532.
24. Swanson MG, Zektzer AS, Tabatabai ZL, et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. *Magn Reson Med*. 2006;55:1257–1264.
25. Shaka AJ, Barker PB, Freeman R. Computer-optimized decoupling scheme for wideband applications and low-level operation. *J Magn Reson*. 1969;1985(64):547–552.
26. Carlos Cobas J, Bernstein MA, Martín-Pastor M, Tahoces PG. A new general-purpose fully automatic baseline-correction procedure for 1D and 2D NMR data. *J Magn Reson*. 2006;183:145–151.
27. Johnson S, Rabinovitch P. Ex vivo imaging of excised tissue using vital dyes and confocal microscopy. *Curr Protoc Cytom*. 2012;Chapter 9:Unit 9.39.
28. Keshari KR, Tsachres H, Iman R, et al. Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage – impact of tissue environment. *NMR Biomed*. 2011;24:691–699.
29. Eidelman E, Twum-Ampofo J, Ansari J, Siddiqui MM. The metabolic phenotype of prostate cancer. *Front Oncol*. 2017;7:806.
30. Choi S, Xue H, Wu R, et al. The MCT4 gene: a novel, potential target for therapy of advanced prostate cancer. *Clin Cancer Res*. 2016;22:2721–2733.
31. Pérttega-Gomes N, Vizcaíno JR, Miranda-Gonçalves V, et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. *BMC Cancer*. 2011;11:519.
32. Pertega-Gomes N, Felisbino S, Massie CE, et al. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. *J Pathol*. 2015;236:517–530.
33. Hao J, Chen H, Madigan Mc, et al. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. *Br J Cancer*. 2010;103:1008–1018.
34. Schiebler ML, Miyamoto KK, White M, Maygarden SJ, Mohler JL. In vitro high resolution 1H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. *Magn Reson Med*. 1993;29:285–291.
35. Sriram R, Gordon J, Baligand C, et al. Non-invasive assessment of lactate production and compartmentalization in renal cell carcinomas using hyperpolarized ¹³C pyruvate MRI. *Cancers (Basel)*. 2018;10:313.
36. Swanson MG, Keshari KR, Tabatabai ZL, et al. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. *Magn Reson Med*. 2008;60:33–40.

37. Elkhaled A, Jalbert LE, Phillips JJ, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. *Sci Transl Med*. 2012;4:116ra5-116ra5.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

TABLE S1 Culture medium formulation

TABLE S2 Sources of culture medium ingredients

TABLE S3 Biopsy tissue NMR measurements: automated HR-MAS shimming routine

TABLE S4 Biopsy media NMR measurements: automated shimming routine

How to cite this article: Bancroft Brown J, Sriram R, VanCricking M, et al. NMR quantification of lactate production and efflux and glutamate fractional enrichment in living human prostate biopsies cultured with [1,6-¹³C₂]glucose. *Magn Reson Med*. 2019;82:566–576. <https://doi.org/10.1002/mrm.27739>